•
Jun 30, 2021
Equillium Q2 2021 Earnings Report
Reported positive topline results from the EQUATE study and announced plans to initiate a Phase 3 pivotal study of itolizumab.
Key Takeaways
Equillium reported second quarter 2021 financial results, highlighted by positive data from the Phase 1b EQUATE study in acute graft-versus-host disease. The company plans to advance to a single, pivotal Phase 3 clinical study.
Announced positive topline results from the EQUATE study in first-line treatment of acute graft-versus-host disease.
Itolizumab continues to demonstrate favorable safety and efficacy profile.
Rapid and durable complete responses resulted in clinically meaningful reduction in corticosteroid use.
Data support clinical advancement of itolizumab in first-line treatment of aGVHD.
Equillium
Equillium
Forward Guidance
Equillium anticipates several catalysts in the second half of 2021 and Q4 2021.
Positive Outlook
- EQUALISE Phase 1b study: interim data from Type B patients (lupus nephritis) expected 2H 2021
- EQUIP Phase 1b study: topline data in uncontrolled asthma expected 2H 2021
- Initiate pivotal study in first-line aGVHD expected Q4 2021